
Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for ... Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5¿-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient's regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression. 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1096 | -32.5609031491 | 0.3366 | 0.3415 | 0.21 | 823211 | 0.26637317 | CS |
4 | -0.393 | -63.3870967742 | 0.62 | 0.7 | 0.21 | 509649 | 0.40309548 | CS |
12 | -0.438 | -65.8646616541 | 0.665 | 2.11 | 0.21 | 10149234 | 0.6345393 | CS |
26 | -4.949 | -95.614374034 | 5.176 | 6.5 | 0.21 | 4945925 | 1.04956255 | CS |
52 | -7.649 | -97.1178263078 | 7.876 | 21.4 | 0.21 | 6002977 | 5.44955323 | CS |
156 | -7.773 | -97.1625 | 8 | 21.4 | 0.21 | 5832495 | 6.36636358 | CS |
260 | -7.773 | -97.1625 | 8 | 21.4 | 0.21 | 5832495 | 6.36636358 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約